Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

Gilead had been the darling of investors a ... has long promised to transform the life sciences, but today, we stand at a critical juncture where this potential is rapidly becoming a reality.

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

In March, Gilead Sciences reported positive results for its ... in cancer trials – that equated to around 1.6 months of extra life, as well as improvements in quality of life measures, including ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

(Reuters) - Gilead Sciences and the U.S. government have settled ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of ...